Fisher Asset Management
GLUE icon

Fisher Asset Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Fisher Asset Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.8M Buy
363,520
+48,658
+15% +$919K ﹤0.01% 424
2026
Q1 		$5.18M Buy
+314,862
New +$6.02M ﹤0.01% 463

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fisher Asset Management's GLUE Position: Q2 2026 in Review

Fisher Asset Management increased its Monte Rosa Therapeutics (GLUE) stake by 15% in Q2 2026, buying an estimated $919K and bringing the position to 363,520 shares worth $8.8M. The position accounts for ﹤0.01% of the portfolio, ranked #424.

Fisher Asset Management first reported a position in GLUE in Q1 2026 and has held it in 2 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Fisher Asset Management held 363,520 shares of Monte Rosa Therapeutics worth $8.8M as of Q2 2026.
  • Fisher Asset Management bought 48,658 Monte Rosa Therapeutics shares in Q2 2026, an estimated $919K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Fisher Asset Management's portfolio in Q2 2026, its #424 holding.
  • Fisher Asset Management first reported a position in Monte Rosa Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Fisher Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.